Tanaka K, Arita H
Shionogi Research Laboratories, Shionogi & Co., Ltd., Osaka, Japan.
Agents Actions Suppl. 1995;46:51-64.
Secretory phospholipase A2 (sPLA2) is now clearly considered to be involved in the pathogenesis of both experimental and clinical inflammatory processes. This has led academic and pharmaceutical industry researchers to expend enormous efforts to identify specific sPLA2 inhibitors to better understand the role of this enzyme in biological systems and to enable its clinical use in the treatment of inflammation and related disorders. Presented here is a brief review of the biological activity of sPLA2 inhibitors and diseases that may be postulated as their possible targets. Also discussed are problems associated with the evaluation of sPLA2 inhibitors for their selectivity and specificity.
分泌型磷脂酶A2（sPLA2）现已被明确认为参与了实验性和临床炎症过程的发病机制。这使得学术界和制药行业的研究人员付出了巨大努力来寻找特异性sPLA2抑制剂，以便更好地理解这种酶在生物系统中的作用，并使其能够在临床上用于治疗炎症及相关疾病。本文简要综述了sPLA2抑制剂的生物学活性以及可能被假定为其潜在靶点的疾病。同时也讨论了评估sPLA2抑制剂的选择性和特异性时所涉及的问题。
